Vanda Pharmaceuticals Inc. - VNDA EV/Sales Multiple

Public company logo of Vanda Pharma (VNDA)

Vanda Pharmaceuticals (VNDA) attracts neurobiologists with its academic culture and stock options, yet suffers from revenue dependence on two legacy products while expanding its immunology pipeline. The company's EV/Sales metric on the GURU.Markets website features this chart, where the value of 450.98 represents the current level of market confidence. Clinic supply efficiency is maintained by outsourcing logistics and production to third-party contractors.

VNDA: vandapharma.com EV/Sales Multiple 11/23/2025 - 11/20/2026

Financial and market metric breakdowns for Vanda Pharmaceuticals Inc (VNDA)

Initial company analysis:Vanda Pharmaceuticals
Mass-produced product of Vanda Pharma

Vanda Pharmaceuticals specializes in developing unique drugs for the therapy of severe neurological and psychiatric pathologies. This indicator determines the market value of the business relative to its annual turnover, excluding the impact of debt load. An analysis of the company's valuation via EV/Sales allows for a comparison of market capitalization with actual revenue flow. This chart reflects whether the asset is overbought or if its monopoly positions are undervalued. For the investor, this is a critical marker of the shares' fundamental attractiveness.